# Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study

> **NCT02844270** · NA · UNKNOWN · sponsor: **Shanghai Bio-heart Biological Technology Co., Ltd.** · enrollment: 45 (estimated)

## Conditions studied

- Heart Diseases

## Interventions

- **DEVICE:** Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

## Key facts

- **NCT ID:** NCT02844270
- **Lead sponsor:** Shanghai Bio-heart Biological Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08-09
- **Primary completion:** 2016-12-22
- **Final completion:** 2021-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02844270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02844270, "Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02844270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*